-
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
-
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure